Pharmaceutical development drug discovery

Wards, R. A., Zhang, K., Firth, L., Benchmarking chemistry functions within pharmaceutical drug discovery and preclinical development, Drug Discovery World Summer 2002,... 

Part 2 Risk Assessment and Addressing Uncertainty in Pharmaceutical New Drug Discovery and Development... 

Fung, M., Thornton, A., Mybeck, K., Hsiao-Hui, W., Hornbuckle, K. and Muniz, E. (2001) Evaluation of the characteristics of safety withdrawal of prescription drugs from worldwide pharmaceutical markets - 1960-1999. Drug Information Journal, 35, 293—317. Dykens, J.A. and Will, Y. (2007) The significance of mitochondrial toxicity testing in drug development. Drug Discovery Today, 12, 777-785. 

Harrigan, G. G. Metabolomics A systems contribution to pharmaceutical discovery and drug development. Drug Discovery World Spring 39 16, 2006. 

Figure 6.1. Schematic showing the various departments in pharmaceutical research discovery research, chemical and pharmaceutical development, drug metabolism and pharmacokinetics (DMPK), and manufacturing quality control. Diagram Courtesy of Waters Corporation.

Schweizer, M., et ah, Somatic gene therapy-advanced biotechnology products in clinical development, in Pharmaceutical Biotechnology - Drug Discovery and Clinical Applications, O. Kayser, R. Muller (eds.). Wiley-VCH, Weinheim, 2004, pp. 231-248. 

Ivanisevic I, Bates S, Chen P (2009) Novel methods for the assessment of miscibility of amorphous drug-polymer dispersions. J Pharm Sci 98 3373-3386 Ivanisevic I, McClurg RB, Schields PJ, Gad SC (2010) Uses of X-ray powder diffraction in the pharmaceutical industry drug discovery, development, and manufacturing, pharmaceutical sciences... 

Combinatorial chemistry, a new chapter of organic synthesis, is now developing rapidly. This new approach to synthesizing large designed or random chemical libraries through application of solid phase synthetic methods, promises to revolutionize the process of drug discovery in the pharmaceutical industry.24... 

Also in the 1980s, structure-based drug design (SBDD) underwent a similar cycle. Early proponents oversold what could be achieved through SBDD, thereby causing pharmaceutical companies to reconsider their investments when they discovered that SBDD too was no panacea for filling the drug discovery cornucopia with choice molecules for development. Nevertheless, SBDD was an important advance. 

As the twentieth century came to a close, the job market for computational chemists had recovered from the 1992-1994 debacle. In fact, demand for computational chemists leaped to new highs each year in the second half of the 1990s [135]. Most of the new jobs were in industry, and most of these industrial jobs were at pharmaceutical or biopharmaceutical companies. As we noted at the beginning of this chapter, in 1960 there were essentially no computational chemists in industry. But 40 years later, perhaps well over half of all computational chemists were working in pharmaceutical laboratories. The outlook for computational chemistry is therefore very much linked to the health of the pharmaceutical industry itself. Forces that adversely affect pharmaceutical companies will have a negative effect on the scientists who work there as well as at auxiliary companies such as software vendors that develop programs and databases for use in drug discovery and development. 

Ruffolo R. Re-engineering discovery and development impact on the pharmaceutical industry of tomorrow. In Drug Discovery Technology Europe 2005, IBC Life Sciences. 

---